Could Patients With Inflammatory Bowel Disease Treated With Immunomodulators or Biologics

Could Patients With Inflammatory Bowel Disease Treated With Immunomodulators or Biologics Be at Lower Risk for Severe Forms of COVID-19?

Fabio Salvatore Macaluso and Ambrogio Orlando

Published Apr 2021, in Gastroenterology.

The Coronavirus Disease 2019 (COVID-19) pandemic is undoubtedly the global health crisis of our time. In this regard, we read with interest the paper by Iago Rodríguez-Lago and colleagues1 on the outcome of patients with inflammatory bowel disease (IBD) during the severe acute respiratory syndrome coronavirus 2 pandemic in the Basque Country, Spain. Interestingly, patients with IBD and COVID-19 had a good overall prognosis, despite that approximately one-third of them were under immunomodulator therapy, and 18% were on biologics.

The interplay between COVID-19 and the medications used for IBD is currently undefined; however, it is well known that several drugs used in patients with IBD may promote the occurrence of infections, including the opportunistic and viral ones. Nonetheless, the specific impact of immunosuppression on the severity of COVID-19 remains unclear. Data reported on 1099 patients from China did not observe immunomodulator use as a risk factor for severe disease.2 Furthermore, the level of immunosuppression, and thus the theoretical risk of developing severe forms of COVID-19, varies depending by the specific drug. In this regard, Infectious Diseases Society of America guidelines distinguish patients with low-level vs high-level immunosuppression,3 and only patients receiving daily corticosteroid therapy with a dosage >20 mg of prednisone or equivalent for >14 days, and those receiving tumor necrosis factor-alpha (TNF-α) inhibitors should be considered as individuals with high-level immunosuppression. We believe that this simple classification is reliable also in patients with IBD. Other drugs are not specifically mentioned by Infectious Diseases Society of America guidelines, as they were developed after the formulation of these indications. Therefore, the gut-specificity of vedolizumab should make the possibility that the drug may increase the risk of COVID-19 complications quite unlikely, whereas the anti-interleukin (IL)-12/23p40 block induced by ustekinumab has been associated with an excellent safety profile.4 Regarding tofacitinib (and JAK inhibitors in general), some concerns may arise due to its potent multicytokine suppressive interference, even if its safety profile in IBD still needs to be clearly defined.5 Recently, the British Society of Gastroenterology published a document of advice for management of IBD during the COVID-19 pandemic.6 The authors distinguished patient risk into highest, moderate, and lowest for COVID-19–related poor outcome. In summary, patients under treatment with any drug used for IBD, with the exception of mesalamine, budesonide, beclomethasone, or rectal therapies, were considered to have at least a moderate risk, whereas they were in the highest risk group if they also had a comorbidity and/or were ≥70 years old. Even if the authors stressed the concept that patients should continue their current medications until different medical advice, we believe that the use of terms such as “moderate” or “highest” risk may induce an unjustified alarmism among doctors and patients, which could lead to erroneously considering the opportunity to reduce or suspend the treatments for IBD, with the potential risk for flares of the disease.

Another relevant point to consider is that, in patients with severe COVID-19, a “cytokine storm” syndrome has been documented: a condition characterized by hyperactivation of T cells and massive production of several ILs. As a consequence, on a purely speculative level, it may be hypothesized that patients with IBD on immunomodulatory treatments, particularly those who directly interfere with cytokine action and production, may be protected even against the severe forms of COVID-19. Indeed, TNF-α is involved in the “cytokine storm” syndrome across key points of the cytokines cascade,7 so that TNF-α inhibitors could be beneficial in this context, at least theoretically. In this line, adalimumab has been proposed as a biologic to test in the management of COVID-19.8 In addition, preliminary evidence supported the use of tocilizumab, an IL-6 receptor antagonist, in the treatment of severe acute respiratory syndrome coronavirus 2–driven pneumonia, and similar effects could be induced by other anti-IL drugs, such as ustekinumab. Similar considerations may be argued also for JAK inhibitors, as their multicytokine block could be beneficial in preventing the “cytokine storm” syndrome. Not by chance, ruxolitinib, a JAK1/2 selective inhibitor used for the treatment of primary myelofibrosis, polycythemia vera, and graft-versus-host disease, has very recently started to be tested for COVID-19.8

In conclusion, the real risk of developing severe forms of COVID-19 in patients with IBD treated with immunomodulators or biologics is currently not defined, and should be clarified by large studies, which will be surely performed in the coming months and years. Although there is never too much prudence when evidence is lacking, excessive alarms should be avoided.


Recent Posts

See All